ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

11.15 +0.30 (+2.76%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2026 Add to My Watchlist

Price and Volume

Volume	34,608
Open	10.95
Bid (Size)	11.00 (500)
Ask (Size)	11.30 (600)
Prev. Close	10.85
Today's Range	10.85 - 11.46
52wk Range	0.2878 - 27.40
Shares Outstanding	32,689,190
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

March 25, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

March 18, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Performance

YTD	+56.3%	+56.3%
1 Month	-13.4%	-13.4%
3 Month	+4.6%	+4.6%
6 Month	+2445.7%	+2445.7%
1 Year	+1748.8%	+1748.8%

More News

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

There are notable gap-ups and gap-downs in today's session. ↗

January 30, 2026

Via Chartmill

Which stocks are moving before the opening bell on Friday? ↗

January 30, 2026

Via Chartmill

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

January 30, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

December 18, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

December 10, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

December 01, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

December 01, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Via Chartmill

Top movers in Monday's session ↗

November 24, 2025

Via Chartmill

The market is filled with gapping stocks in Monday's session. ↗

November 24, 2025

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

November 24, 2025

Via Chartmill

ProMIS Neurosciences Announces Reverse Stock Split

November 24, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 19, 2025

Via Benzinga

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

November 12, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

November 03, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

October 22, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 05, 2025

Via Benzinga

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

September 03, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

August 13, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

EXCLUSIVE: July's 20 Most-Searched Tickers On Benzinga Pro — Where Do Opendoor, Nvidia, Apple Stock Rank? ↗

August 01, 2025

Via Benzinga

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference

July 29, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Frequently Asked Questions

Is ProMIS Neurosciences Inc. - Common Shares publicly traded?

Yes, ProMIS Neurosciences Inc. - Common Shares is publicly traded.

What exchange does ProMIS Neurosciences Inc. - Common Shares trade on?

ProMIS Neurosciences Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for ProMIS Neurosciences Inc. - Common Shares?

The ticker symbol for ProMIS Neurosciences Inc. - Common Shares is PMN on the Nasdaq Stock Market

What is the current price of ProMIS Neurosciences Inc. - Common Shares?

The current price of ProMIS Neurosciences Inc. - Common Shares is 11.15

When was ProMIS Neurosciences Inc. - Common Shares last traded?

The last trade of ProMIS Neurosciences Inc. - Common Shares was at 04/29/26 04:00 PM ET

What is the market capitalization of ProMIS Neurosciences Inc. - Common Shares?

The market capitalization of ProMIS Neurosciences Inc. - Common Shares is 364.48M

How many shares of ProMIS Neurosciences Inc. - Common Shares are outstanding?

ProMIS Neurosciences Inc. - Common Shares has 364M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.